2 Vaccine Stocks With High Potential

Discovered just a few weeks ago, the omicron variant is the dominant Covid-19 strain in the United States, accounting for roughly 73% of cases. "We are working with Pfizer, Moderna and (Johnson & Johnson) to develop contingency plans for changes to vaccines or boosters if needed," said Jeff Zients, the White House's Covid-19 response coordinator, last month. With the rapid spread of the new variant in various parts of the world, the demand for Covid-19 vaccines and booster vaccines is expected to increase significantly. Therefore, Pfizer Inc. (PFE) and BioNTech SE (BNTX) we think it would be wise to invest in quality Covid-19 vaccine stocks. Especially with the emergence of the omicron variant, both companies made significant gains. And these stocks are expected to continue to recover in the coming months.

Pfizer Inc. (PFE)

PFE offers drugs and vaccines in a variety of therapeutic areas, including cardiovascular, metabolic, pain, biologic, small molecules and immunotherapies. On December 8, PFE and BNTX announced that three-step administration of Covid-19 vaccines in a laboratory test could neutralize the omicron variant; this is an early signal that booster vaccines could be crucial protection against infection from the newly identified variant. Analysts expect PFE's revenue to increase 13.2% year-over-year to $845.99 billion for fiscal 2022. In addition, EPS is expected to increase 26.9% year-on-year to $49.05 next year.

BioNTech SE (BNTX)

Headquartered in Mainz, Germany, BNTX is a biotechnology company that develops and commercializes immunotherapies for cancer and infectious diseases. It creates a broad product line using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, targeted cancer antibodies and small molecules. France's Haute Autorite de Sante (HAS) health regulator approved the PFE-BNTX Covid-19 vaccine for all children aged 5 to 11 on 20 December. Since the European Medicines Agency (EMA) approved the use of a low dose of PFE-BNTX, many countries in the European Union that had vaccinated 5-11 year olds last month have started to vaccinate children in this age group. Analysts expect BNTX's revenue for fiscal 2021 to be $19.8 billion, up 3,255.6 percent year on year. The company's EPS is expected to rise 59,185.7% year-on-year to $41.5 in fiscal 2021.   2 Vaccine Stocks With High Potential Source: Stocknews.com